abrdn Life Sciences Investors (NYSE:HQL) Shares Shorted: Short Interest Up 70.8% in October

abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 192,658 shares, a growth of 70.8% from the September 30th total of 112,812 shares. Based on an average daily trading volume, of 139,589 shares, the short-interest ratio is currently 1.4 days. Approximately 0.7% of the company’s stock are short sold.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. KPP Advisory Services LLC raised its stake in abrdn Life Sciences Investors by 2.7% in the second quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock valued at $505,000 after purchasing an additional 660 shares in the last quarter. 180 Wealth Advisors LLC lifted its stake in shares of abrdn Life Sciences Investors by 2.2% in the 2nd quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after acquiring an additional 3,271 shares during the last quarter. Wedbush Securities Inc. boosted its stake in shares of abrdn Life Sciences Investors by 21.1% during the third quarter. Wedbush Securities Inc. now owns 19,335 shares of the company’s stock valued at $362,000 after purchasing an additional 3,375 shares in the last quarter. Provenance Wealth Advisors LLC bought a new stake in abrdn Life Sciences Investors during the 3rd quarter worth approximately $66,000. Finally, NewEdge Advisors LLC grew its stake in shares of abrdn Life Sciences Investors by 17.6% in the first quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock worth $387,000 after purchasing an additional 3,562 shares during the last quarter. 32.21% of the stock is owned by institutional investors.

abrdn Life Sciences Investors Stock Down 2.5%

HQL opened at $17.98 on Tuesday. abrdn Life Sciences Investors has a 12-month low of $15.66 and a 12-month high of $22.67. The stock’s 50 day moving average price is $19.00 and its two-hundred day moving average price is $18.24.

abrdn Life Sciences Investors Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Monday, August 24th were given a $0.62 dividend. The ex-dividend date was Monday, August 24th. This represents a $2.48 annualized dividend and a dividend yield of 13.8%.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors is a publicly traded closed-end investment company listed on the New York Stock Exchange under the symbol HQL. The fund seeks long-term capital appreciation by investing in companies involved in the life sciences industry.

Its portfolio may include businesses across biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services and related fields. The fund can invest in both publicly traded and privately held companies, providing shareholders with diversified exposure to innovative healthcare and life sciences businesses.

The fund was formerly known as Tekla Life Sciences Investors and adopted the abrdn name following the integration of Tekla’s investment management activities into abrdn.